Recombinant human serum albumin (OsrHSA) has emerged as a big innovation in the sector of biopharmaceuticals, offering promising improvements throughout many clinical and industrial purposes. With its structural similarity to Obviously derived human serum albumin, OsrHSA presents a safer, far more dependable choice for therapeutic use, specifically